Aromatic-Cationic Peptide Stabilizes Glomerular Basement Membrane
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alport Syndrome, caused by mutations in the COL4A3, COL4A4, and COL4A5 genes, leads to progressive kidney disease, hearing loss, and eye abnormalities, with no known cure and current treatments only providing symptomatic relief.
Innovation Solution
Administering a therapeutically effective amount of the aromatic-cationic peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or its pharmaceutically acceptable salt to subjects with Alport Syndrome, either alone or in combination with additional therapeutic agents such as ACE inhibitors, ARBs, or HMG-CoA reductase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments (ACE inhibitors, dialysis) are used for Alport Syndrome, then patient symptoms are temporarily relieved, but the progressive kidney disease continues to worsen leading to end-stage renal disease
Solution Approach 1:
The patent introduces an aromatic-cationic peptide as a mediator that binds to heparan sulfate proteoglycans in the glomerular basement membrane, thereby stabilizing the structure and preventing disease progression. This intermediary mechanism addresses the limitation of current treatments by providing a molecular-level intervention that directly targets the underlying structural defect rather than merely managing symptoms
Solution Approach 2:
The therapeutic peptide utilizes the body's existing heparan sulfate proteoglycans as part of its mechanism of action, leveraging natural biological components to achieve therapeutic effect. The peptide works by binding to and stabilizing the endogenous extracellular matrix structures, allowing the body's own tissues to resist further degradation without requiring external replacement or complex intervention systems
2Adaptability or versatility
If no specific cure is available for Alport Syndrome, then patients can manage with conventional symptomatic relief, but they inevitably progress to end-stage kidney disease requiring dialysis or transplantation
Solution Approach 1:
The patent changes the therapeutic parameter from symptomatic management to structural stabilization by introducing a peptide that specifically targets and stabilizes the glomerular basement membrane. This parameter change provides a new treatment dimension that addresses the root cause of progression rather than merely managing clinical symptoms, thereby improving disease outcome reliability
3Strength
If the type IV collagen alpha3-4-5 network is defective due to gene mutations, then basement membrane structure is compromised, but no effective therapeutic intervention exists to restore or stabilize the structure
Solution Approach 1:
The aromatic-cationic peptide serves as a mediator that binds to heparan sulfate proteoglycans, providing structural stabilization to the compromised basement membrane. This intermediary approach allows restoration of membrane integrity without requiring correction of the underlying genetic defect or direct replacement of defective type IV collagen, thereby achieving structural strength improvement with feasible therapeutic intervention
Data Source
AI summary
The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.